SPDR® S&P Biotech ETF company info

What does SPDR® S&P Biotech ETF do?
SPDR® S&P Biotech ETF (NYSE:XBI) is a passively managed exchange-traded fund designed to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index. Primarily focused on the biotech sector of the U.S. equity market, it includes companies engaged in research, development, manufacturing, and distribution of various biotechnological products. Projects under the ETF span a diverse range of therapeutic areas, aiming to capitalize on the growth and innovations within the biotech industry. The objective of XBI is to provide investors with a transparent and cost-efficient way to gain exposure to the biotechnology sector, betting on the potential breakthroughs and advancements in the field to drive returns.
SPDR® S&P Biotech ETF company media
Company Snapshot

Is SPDR® S&P Biotech ETF a public or private company?

key
Ownership
Public

How many people does SPDR® S&P Biotech ETF employ?

people
Employees
2,296

What sector is SPDR® S&P Biotech ETF in?

pie chart
Sector
ETF

Where is the head office for SPDR® S&P Biotech ETF?

location pin
Head Office
Boston, United States

What year was SPDR® S&P Biotech ETF founded?

founded flag
Year Founded
2006
What does SPDR® S&P Biotech ETF specialise in?
/Equity Investments /Biotechnology Exposure /Portfolio Diversification /Long-term Growth /Market Index Tracking /Risk Management

What are the products and/or services of SPDR® S&P Biotech ETF?

Overview of SPDR® S&P Biotech ETF offerings
Tracks the S&P Biotechnology Select Industry Index: The ETF replicates the performance of this index, which focuses on publicly traded companies in the US biotechnology sector.
Invests in various biotech segments: The index includes companies involved in diverse areas like pharmaceuticals, medical devices, diagnostics, and agricultural biotechnology.
Provides broad exposure: XBI offers diversification across the US biotech industry, allowing investors to participate in the potential growth of the sector without picking individual stocks.
Passively managed: The ETF passively follows the index composition, not actively selecting individual companies.
Aims for capital appreciation: XBI seeks to grow in value over time by reflecting the potential growth of the underlying biotech companies.
Carries inherent risks: Like any investment, XBI involves risks such as market fluctuations, potential tracking error (underperformance compared to the underlying index), and the inherent risks associated with the biotechnology sector, which can be volatile and sensitive to scientific advancements and regulatory changes.